sildenafil · Revatio
Small molecule
Evidence outlook
Approved: Pulmonary Arterial Hypertension
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Pediatric Patients (1 to 17 Years Old) REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14) ] . Adults REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clin
- REVATIO (sildenafil citrate) is indicated for: • treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilised on background epoprostenol therapy. REVATIO solution is indicated for: • the continued treatment of patients with pulmonary arterial hypertension (PAH) who are currently...
- Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Paediatric population Treatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00644605 NCT00644605 · Hypertension, Pulmonary Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT00644605 | 3 | Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test). (Week 12) | The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). | Partial signal | link ↗ |
View 6 more trials
NCT00159861 NCT00159861 · Pulmonary Hypertension PACES was a 16-week, randomized, double-blind, placebo-controlled trial in 267 patients with pulmonary arterial hypertension on long-term intravenous epoprostenol, adding sildenafil 20 mg titrated to 80 mg three times daily or placebo. The primary endpoint was change in 6-minute walk distance. Sildenafil increased it by 28.8 m over placebo (95% CI 13.9 to 43.8), so the primary was met; time to clinical worsening was also longer (P=0.002). The CT.gov results cover the open-label extension and post only categorized long-term walk changes without a test. Source: Simonneau et al., Ann Intern Med 2008. Registry: NCT00159861 | 3 | Categorized Change From Baseline in 6-Minute Walking Distance (1 Year, 2 Year, 3 Year) | 6-minute walk distance change at week 16 (core-study primary), sildenafil added to long-term IV epoprostenol vs placebo: placebo-adjusted +28.8 m (95% CI 13.9 to 43.8) (Simonneau et al., Ann Intern Med 2008). CT.gov posts only the extension's categorized 6MWD change at years 1 to 3. | Partial signal | link ↗ |
NCT00159887 NCT00159887 · Pulmonary Arterial Hypertension Registry: NCT00159887 | 3 | Safety; Standard safety data; Efficacy; 6-Minute Walk Test; BORG Dyspnoea Score; WHO Functional Class; Quality of Life SF-36 and EQ-5D | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT00159913 NCT00159913 · Pulmonary Arterial Hypertension This was a randomized, triple-blind, placebo-controlled trial, but its primary comparison of combined sildenafil doses against placebo on exercise capacity was not statistically significant (p=0.056). A well-run trial with a borderline miss is real evidence, but not strong evidence that the drug works. Registry: NCT00159913 | 3 | Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population (Baseline, Week 16); Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population (Baseline, Week 16) 2008-06 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00159874 NCT00159874 · Pulmonary Arterial Hypertension This study continued children who completed the randomized, double-blind STARTS-1 trial, so it builds on a controlled population, but it was open-label with no placebo group and measured only safety outcomes. It describes long-term safety by dose; it was not built to test whether sildenafil works. Registry: NCT00159874 | 3 | Number of Participants Reporting at Least One Adverse Event (Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)); Number of Participants Reporting Treatment-related Adverse Events (Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)); Number of Participants Reporting at Least One Serious Adverse Event (Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)); Number of Participants Reporting Treatment-related Serious Adverse Events (Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)); Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration (Pre-DMC Recommendation dose down titration (04 August 2011)); Number of Deaths Reported During This Study (Last follow-up visit or 30 days after the last administration of study drug); Discontinuation Due to Intolerability (Throughout the treatment duration (median treatment duration 1689 to 1744 days)); Downtitration in Dose Due to Intolerability. (Pre-DMC recomendation (04 August 2011)); Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests (Week 36); Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests. (Week 36); Pediatric Cognitive Development Status at Week 16.; Pediatric Cognitive Development Status at Week 52.; Pediatric Motor Development Status at Week 16.; Pediatric Motor Development Status at Week 52 2012-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00323297 NCT00323297 · Pulmonary Arterial Hypertension Registry: NCT00323297 | 4 | Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12 2013-08 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
AFFILIATE NCT02060487 · Pulmonary Arterial Hypertension Registry: NCT02060487 | 4 | Overall Survival (Day 1 of study treatment up to date of death (within a maximum duration of 2102 days)) 2021-02-26 | Stopped early (terminated). Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (61)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (71)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (77)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (97)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (52)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (20)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (6)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other PDE5 drugs
Tadalafil, AR1001, Udenafil, RTN-001. Compare all 5 PDE5 drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sildenafil (Revatio): this drug | Approved | Small molecule | PDE5 | Partial signal | NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). | |
| Ambrisentan (Letairis) | Approved | Small molecule | Endothelin A receptor | Reliable signal | NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001). | |
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant) NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults. | |
| Epoprostenol (Flolan) | ApprovedUS marketing discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Macitentan (Opsumit) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Partial signal | NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier | |
| Riociguat (Adempas) | Approved | Small molecule | Soluble guanylate cyclase | Reliable signal | NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5) | |
| Sotatercept (Winrevair) | Approved | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | Reliable signal | NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | |
| Tadalafil (Adcirca) | Approved | Small molecule | PDE5 | Weak signal | NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks. | |
| Treprostinil (Orenitram) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) | |
| Treprostinil (Remodulin) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | Featured results are safety only in this race | |
| AR1001 | Phase 3(overall) | Small molecule | PDE5 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3 | Small molecule | Calcineurin | not yet graded | No reviewed efficacy summary in this indication | |
| Imatinib Mesylate Prodrug (IkT-001Pro) | Phase 3 | Small molecule | PDGFR (imatinib-class) | not yet graded | No reviewed efficacy summary in this indication | |
| Ralinepag | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. | |
| Seralutinib | Phase 3 | Small molecule | PDGFR/CSF1R/KIT (multi-kinase) | Partial signal | NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Udenafil (Zydena) | Phase 2/3 | Small molecule | PDE5 | Weak signal | No reviewed efficacy summary in this indication | |
| APL-9796 | Phase 2 | Monoclonal antibody | ZIP12 (zinc transporter) | not yet graded | No reviewed efficacy summary in this indication | |
| ROC-101 | Phase 2 | Small molecule | Rho-associated kinase (ROCK, pan) | not yet graded | No reviewed efficacy summary in this indication | |
| RTN-001 | Phase 2(overall) | Small molecule | PDE5 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Vasigrobart | Phase 2 | Monoclonal antibody | PDGF-B | not yet graded | No reviewed efficacy summary in this indication | |
| Zamicastat | Phase 2 | Small molecule | DBH | Weak signal | No reviewed efficacy summary in this indication | |
| HS235 | Phase 1/2 | Peptide | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary in this indication | |
| F230 | —(overall) | Small molecule | Endothelin A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6792070 | —(overall) | Undisclosed | Activin signalling | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | Weak signal | NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1) | |
| PF-07868489 | Discontinued | Protein / enzyme therapeutic | Bone morphogenetic protein 9 (BMP9) | Partial signal | No reviewed efficacy summary in this indication |
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Revatio (sildenafil) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.